SuperworthJohnson & Johnson EPS JNJ
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Sep 27, 2026
- $6.60
- Latest quarter, Q3 FY26
- $0.09
- −96% on a year earlier
- Fiscal year 2025
- $11.05
- +91% on the year before
Johnson & Johnson's earnings per share was $6.60 over the twelve months to Sep 27, 2026, down 36% on a year earlier.
In its latest quarter, Q3 FY26, it was $0.09, down 96% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 15% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $11.05 | +91% |
| FY2024 | $5.79 | −58% |
| FY2023 | $13.81 | +105% |
| FY2022 | $6.74 | −14% |
| FY2021 | $7.81 | +42% |
| FY2020 | $5.51 | −2% |
| FY2019 | $5.63 | +0% |
| FY2018 | $5.61 | +1338% |
| FY2017 | $0.39 | −93% |
| FY2016 | $5.93 | +8% |
| FY2015 | $5.49 | −4% |
| FY2014 | $5.70 | +18% |
| FY2013 | $4.82 | +25% |
| FY2012 | $3.87 | +11% |
| FY2011 | $3.48 | −27% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0.09 | −96% | $6.60 | |
| Q2 FY26 | $2.27 | −1% | $8.63 | |
| Q1 FY26 | $2.14 | −53% | $8.65 | |
| Q4 FY25 | $2.10 | +49% | $11.05 | |
| Q3 FY25 | $2.12 | +91% | $10.36 | |
| Q2 FY25 | $2.29 | +19% | $9.35 | |
| Q1 FY25 | $4.54 | +239% | $8.99 | |
| Q4 FY24 | $1.41 | −16% | $5.79 | |
| Q3 FY24 | $1.11 | −89% | $6.05 | |
| Q2 FY24 | $1.93 | −2% | $15.15 | |
| Q1 FY24 | $1.34 | n/a | $15.18 | |
| Q4 FY23 | $1.67 | +26% | $13.81 |
Against its peers
Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| JNJJohnson & Johnson | $6.60 | −36% a year |
| ABBVAbbVie | $3.54 | +69% a year |
| MRKMerck | $1.25 | −81% a year |
| LLYEli Lilly and | $29.80 | +95% a year |
| AMGNAmgen | $16.09 | +32% a year |
| GILDGilead Sciences | −$2.67 | −153% a year |
| PFEPfizer | $0.76 | −60% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| Peer median | $3.54 |
Where Johnson & Johnson ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Johnson & Johnson
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.